These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26471487)

  • 1. Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
    Chang SC; Lin PC; Lin JK; Lin CH; Yang SH; Liang WY; Chen WS; Jiang JK
    Ann Surg Oncol; 2016 Mar; 23(3):849-55. PubMed ID: 26471487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
    Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of mucinous components correlated with microsatellite instability in patients with colorectal cancer.
    Yoon YS; Kim J; Hong SM; Lee JL; Kim CW; Park IJ; Lim SB; Yu CS; Kim JC
    Colorectal Dis; 2015 Aug; 17(8):O161-7. PubMed ID: 26095997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features of gastric cancer with synchronous and metachronous colorectal cancer in Korea: are microsatellite instability and p53 overexpression useful markers for predicting colorectal cancer in gastric cancer patients?
    Kim HJ; Kim N; Choi YJ; Yoon H; Shin CM; Park YS; Lee HS; Ahn SH; Park do J; Kim HH; Son IT; Kang SB; Lee DH
    Gastric Cancer; 2016 Jul; 19(3):798-807. PubMed ID: 26445944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular differences in colorectal cancer according to location.
    Hsu YL; Lin CC; Jiang JK; Lin HH; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Lin JK; Lin PC; Chang SC
    Int J Biol Markers; 2019 Mar; 34(1):47-53. PubMed ID: 30854932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas.
    Koinuma K; Shitoh K; Miyakura Y; Furukawa T; Yamashita Y; Ota J; Ohki R; Choi YL; Wada T; Konishi F; Nagai H; Mano H
    Int J Cancer; 2004 Jan; 108(2):237-42. PubMed ID: 14639609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.